Table 3.
Analysis of heterogeneity.
| t1 | t2 | i2.pair | i2.cons | incons.p |
|---|---|---|---|---|
| Myocardial infarction | ||||
| Per-comparison I-squared: | ||||
| DPP4_inhibitors | GLP1_agonists | 0 | 0 | 0.68 |
| DPP4_inhibitors | Placebo | 32.12 | 24.82 | 0.91 |
| DPP4_inhibitors | SGLT2_inhibitors | 44.39 | 44.38 | NA |
| DPP4_inhibitors | Sulfonylureas | 15.62 | 5.24 | 0.58 |
| GLP1_agonists | Insulin | 44.14 | 44.27 | NA |
| GLP1_agonists | Placebo | 0 | 0 | 0.86 |
| GLP1_agonists | Sulfonylureas | 0 | 0 | 0.56 |
| Global I-squared: | ||||
| 19.40 | 15.67 | |||
| Angina | ||||
| Per-comparison I-squared: | ||||
| DPP4_inhibitors | GLP1_agonists | 67.00 | 52.20 | 0.47 |
| DPP4_inhibitors | Placebo | 0 | 0 | NA |
| DPP4_inhibitors | SGLT2_inhibitors | 46.17 | 47.17 | NA |
| DPP4_inhibitors | Sulfonylureas | 6.98 | 0 | 0.76 |
| GLP1_agonists | Insulin | 33.38 | 33.05 | NA |
| GLP1_agonists | Sulfonylureas | 61.08 | 33.03 | 0.53 |
| Global I-squared: | ||||
| 30.56 | 26.56 | |||
| Coronary arterial diseases | ||||
| Per-comparison I-squared: | ||||
| DPP4_inhibitors | GLP1_agonists | 0 | 19.84 | 0.05 |
| DPP4_inhibitors | Placebo | 0 | 0 | NA |
| DPP4_inhibitors | SGLT2_inhibitors | 34.72 | 34.67 | NA |
| DPP4_inhibitors | Sulfonylureas | 32.50 | 28.73 | 0.16 |
| GLP1_agonists | Insulin | 31.44 | 30.88 | NA |
| GLP1_agonists | Sulfonylureas | 0 | 13.46 | 0.09 |
| Global I-squared: | ||||
| 19.96 | 16.26 | |||
t1: treatment 1, t2: treatment 2, i2.pair: i-square of pair-wise meta-analysis, i2.cons: i-square of network meta-analysis, incons.p: inconsistency p-values for pair-wise and network meta-analysis NA: not applicable.